title: U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.
abstract: Bisheteroarylpiperazines are potent inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). We describe a novel bisheteroarylpiperazine, U-90152 [1-(5-methanesulfonamido-1H-indol-2-yl-carbonyl)-4-[3-(1-methyl eth yl-amino)pyridinyl]piperazine], which inhibited recombinant HIV-1 RT at a 50% inhibitory concentration (IC50) of 0.26 microM (compared with IC50s of > 440 microM for DNA polymerases alpha and delta). U-90152 blocked the replication in peripheral blood lymphocytes of 25 primary HIV-1 isolates, including variants that were highly resistant to 3'-azido-2',3'-dideoxythymidine (AZT) or 2',3'-dideoxyinosine, with a mean 50% effective dose of 0.066 +/- 0.137 microM. U-90152 had low cellular cytotoxicity, causing less than 8% reduction in peripheral blood lymphocyte viability at 100 microM. In experiments assessing inhibition of the spread of HIV-1IIIB in cell cultures, U-90152 was much more effective than AZT. When approximately 500 HIV-1IIIB-infected MT-4 cells were mixed 1:1,000 with uninfected cells, 3 microM AZT delayed the evidence of rapid viral growth for 7 days. In contrast, 3 microM U-90152 totally prevented the spread of HIV-1, and death and/or dilution of the original inoculum of infected cells prevented renewed viral growth after U-90152 was removed at day 24. The combination of U-90152 and AZT, each at 0.5 microM, also totally prevented viral spread. Finally, although the RT amino acid substitutions K103N (lysine 103 to asparagine) and Y181C (tyrosine 181 to cysteine), which confer cross-resistance to several nonnucleoside inhibitors, also decrease the potency of U-90152, this drug retains significant activity against these mutant RTs in vitro (IC50s, approximately 8 microgramM).
authors.affiliation: Upjohn Laboratories, Kalamazoo, Michigan 49001-0199, USA.
authors.forename: T J
authors.initials: TJ
authors.lastname: Dueweke
authors.forename: S M
authors.initials: SM
authors.lastname: Poppe
authors.forename: D L
authors.initials: DL
authors.lastname: Romero
authors.forename: S M
authors.initials: SM
authors.lastname: Swaney
authors.forename: A G
authors.initials: AG
authors.lastname: So
authors.forename: K M
authors.initials: KM
authors.lastname: Downey
authors.forename: I W
authors.initials: IW
authors.lastname: Althaus
authors.forename: F
authors.initials: F
authors.lastname: Reusser
authors.forename: M
authors.initials: M
authors.lastname: Busso
authors.forename: L
authors.initials: L
authors.lastname: Resnick
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D020008:Delavirdine; D004352:Drug Resistance, Microbial; D015658:HIV Infections / Q000188:drug therapy / Q000382:microbiology; D054303:HIV Reverse Transcriptase; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000502:physiology; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D010879:Piperazines / Q000494:pharmacology*; D012194:RNA-Directed DNA Polymerase / Q000235:genetics; D018894:Reverse Transcriptase Inhibitors; D013601:T-Lymphocytes / Q000187:drug effects / Q000382:microbiology; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D007211:Indoles; D010879:Piperazines; D018894:Reverse Transcriptase Inhibitors; D020008:Delavirdine; D054303:HIV Reverse Transcriptase; D012194:RNA-Directed DNA Polymerase